Trial Condition(s):

Hypertension, Pulmonary

A study to understand the treatment patterns in patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension during a switch of treatment to Adempas in real-life clinical practice (CAPTURE)

Bayer Identifier:

17983

ClinicalTrials.gov Identifier:

NCT02545465

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching

Inclusion Criteria
- Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice
 - Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy

Trial Summary

Enrollment Goal
125
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 
Locations

Investigative Site

Many Locations, Canada

Status
Completed
 
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 
Locations

Investigative Site

Many Locations, Sweden

Status
Completed
 
Locations

Investigative Site

Many Locations, Turkey

Status
Completed
 
Locations

Investigative Site

Many Locations, Colombia

Status
Completed
 

Trial Design